Galena Biopharma Given New $6.00 Price Target at Noble Financial (GALE)
Noble Financial hoisted their price objective on shares of Galena Biopharma (NASDAQ:GALE) from $4.00 to $6.00 in a research note issued on Monday, Analyst Ratings News reports. The firm currently has a “buy” rating on the stock. Noble Financial’s price objective suggests a potential upside of 13.85% from the stock’s previous close.
In other Galena Biopharma news, COO Mark W. Schwartz unloaded 100,000 shares of Galena Biopharma stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $5.57, for a total value of $557,000.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.
Galena Biopharma (NASDAQ:GALE) opened at 5.27 on Monday. Galena Biopharma has a 52-week low of $1.65 and a 52-week high of $7.77. The stock has a 50-day moving average of $5.33 and a 200-day moving average of $3.13. The company’s market cap is $554.6 million.
A number of other analysts have also recently weighed in on GALE. Analysts at Maxim Group raised their price target on shares of Galena Biopharma from $9.00 to $11.00 in a research note to investors on Tuesday, January 21st. They now have a “buy” rating on the stock. Separately, analysts at Needham & Company raised their price target on shares of Galena Biopharma to $9.00 in a research note to investors on Tuesday, January 21st. Finally, analysts at Roth Capital raised their price target on shares of Galena Biopharma from $11.00 to $12.00 in a research note to investors on Tuesday, January 14th. Five equities research analysts have rated the stock with a buy rating, The stock presently has a consensus rating of “Buy” and an average target price of $7.64.
Galena Biopharma, Inc (NASDAQ:GALE), formerly RXi Pharmaceuticals Corporation, is a biotechnology company focused on discovering, developing and commercializing therapies addressing unmet medical needs using RNAi-targeted and immunotherapy technologies.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.